If you are looking for some ASX growth share to buy with major upside potential, then read on.
Listed below are three that brokers currently rate as buys and have price target meaningfully higher than where they currently trade.
Here's what they are bullish on:
Image source: Getty Images
Breville Group Ltd (ASX: BRG)
The first ASX growth share to look at is Breville.
It has built a global appliances business around premium design, strong branding, and products that sit in everyday kitchen categories. Its range includes coffee machines, food preparation products, cooking appliances, and other home-focused products.
The company's opportunity is not limited to Australia. Breville has been expanding internationally for years, giving it exposure to large overseas markets where its brand can keep building recognition.
This gives the business a long growth runway if it can continue launching popular products, expanding distribution, and protecting margins.
Morgans is positive on the company and has a buy rating and $36.75 price target on its shares. Based on the current Breville share price, this implies potential upside of approximately 20%.
Catapult Group International Ltd (ASX: CAT)
Another ASX growth share that brokers rate as a buy is Catapult.
It provides performance technology for sporting teams and athletes. Its products help clubs measure movement, workload, training intensity, match output, and other performance data.
This places Catapult in a niche but global market. Professional sport is increasingly data-driven, with teams looking for small advantages in preparation, recovery, injury prevention, and tactical analysis.
The company has a very large growth runway if it can become more deeply embedded in the daily operations of teams, leagues, and performance departments. That can make its software and data increasingly valuable over time. It also gives Catapult room to improve the quality of its revenue as more customers use its platform across multiple products.
Morgans has a buy rating and $5.40 price target on Catapult shares. Compared with the current share price of $3.15, this suggests potential upside of approximately 71%.
Pro Medicus Ltd (ASX: PME)
A third ASX growth share to consider is Pro Medicus.
The medical imaging software provider has become one of the ASX's standout technology success stories. Its Visage platform is used by hospitals and radiology networks to view, manage, and interpret large medical imaging files.
This is a demanding area of healthcare technology. Speed, reliability, image quality, and integration all matter because clinicians need systems they can trust.
Its shares are often priced for high expectations, so volatility should be expected. But the company's margins, execution record, and global opportunity make it worthy of holding tightly to for the long term.
Bell Potter has a buy rating and $226.00 price target on Pro Medicus shares. Based on its current share price of $164.55, this implies potential upside of approximately 37%.
